Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 7 , Pages 831-839 , July 2007

Adherence to Pharmacological Treatment for Juvenile Bipolar Disorder

,Accepted 22 February 2007.

REFERENCES 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994;
  2. Bandura A. Self-Efficacy: The Exercise of Control. New York: Freeman; 1997;
  3. Coletti DJ, Leigh E, Galleli KA, Kafantaris V. Patterns of adherence to treatment in adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15:913–917
  4. DelBello MP, Geller B. Review of studies of child and adolescent offspring of bipolar parents. Bipolar Disord. 2001;3:325–334
  5. Dunn G, Maracy M, Tomenson B. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res. 2005;14:369–395
  6. Erdfelder E, Faul F, Buchner A. GPOWER: a general power analysis program. Behav Res Methods Instruments Comput. 1996;28:1–11
  7. Findling RL, Gracious BL, McNamara NK, et al. Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord. 2001;3:202–210
  8. Findling RL, McNamara NK, Gracious BL, et al. Combination lithium and divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry. 2003;42:895–901
  9. Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:409–417
  10. Geller B, Tillman R, Craney JL, Bohofner K. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch Gen Psychiatry. 2004;61:459–467
  11. Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q. 1984;11:1–47
  12. Jo B. Statistical power in randomized intervention studies with noncompliance. Psychol Methods. 2002;7:178–193
  13. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SDADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988
  14. Kowatch RA, DelBello MP. Pediatric bipolar disorder: emerging diagnostic and treatment approaches. Child Adolesc Psychiatry Clin N Am. 2006;15:73–108
  15. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213–235
  16. Maddux JE, DuCharme KA. Behavioral intentions in theories of health behavior. In:  Gochman DS editors. Handbook of Health Behavior Research: I. Personal and Social Determinants. New York: Plenum; 1997;p. 133–152
  17. Miller I, Bishop D, Epstein N, Kreitner G. The McMaster Family Assessment Device: reliability and validity. J Marital Fam Ther. 1985;11:345–356
  18. Orvaschel H (1994), Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version, fifth revision. Ft. Lauderdale, FL: Nova Southeastern University. Available from orvasche@nova.edu
  19. Patel NC, DelBello MP, Keck PE, Strakowski SM. Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15:938–946
  20. Poznanski EO, Freeman LN, Mokros HB. Children's depression rating scale-revised. Psychopharmacol Bull. 1985;2:979–989
  21. Quittner AL, Espelage DC, Ievers-Landis CE, Drotar D. Measuring adherence to medical treatments in childhood chronic illness: considering multiple methods and sources of information. J Clin Psychol Med Settings. 2000;7:41–54
  22. Rapoff MA. Adherence to Pediatric Medical Regimens. New York: Kluwer Academic/Plenum; 1999;
  23. Rey JM, Singh M, Hung SF, et al. A global scale to measure the quality of the family environment. Arch Gen Psychiatry. 1997;54:817–822
  24. Riekert KA, Drotar D. Adherence to medical treatment in pediatric chronic illness: critical issues and unanswered questions. In:  Drotar D editors. Promoting Adherence to Treatment in Pediatric Chronic Illness: Concepts, Methods, and Interventions. Mahwah, NJ: Erlbaum; 2000;p. 201–231
  25. Robiner WN. Enhancing adherence in clinical research. Contemp Clin Trials. 2005;26:59–77
  26. Romero S, Delbello MP, Soutullo CA, Stanford K, Strakowski SM. Family environment in families with versus families without parental bipolar disorder: a preliminary comparison study. Bipolar Disord. 2005;7:617–622
  27. Shaffer D, Gould MS, Brasic J, et al. A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry. 1983;40:1228–1231
  28. Wolf DV, Wagner KD. Bipolar disorder in children and adolescents. CNS Spectr. 2003;8:954–959
  29. Wozniak J, Biederman J, Richards JA. Diagnostic and therapeutic dilemmas in the management of pediatric-onset bipolar disorder. J Clin Psychiatry. 2001;62(Suppl 14):10–15
  30. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435

 The Stanley Medical Research Institute primarily supported this study. It was also supported in part by an NIMH Developing Centers for Interventions and Services Research Grant (P20 MH-66054), NIHT32 HD041923-05, NIHT32 HD041923-05. Medications for the clinical trial were provided in part by Abbott Laboratories. The work of Susan Wood in processing this manuscript is gratefully acknowledged.Disclosure: Dr. Calabrese has received pharmaceutical income, research grant support, honoraria, and compensation for consultation from Abbott, AstraZeneca, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson Pharmaceutical Research & Development, Solvay/Wyeth, Bristol-Myers Squibb, and Eli Lilly. Dr. Findling receives or has received research support from, acted as a consultant to, and/or served on the speakers' bureaus of Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka, Pfizer, Sanofi-Aventis, Shire, Solvay, and Wyeth. The other authors have no financial relationships to disclose.

PII: S0890-8567(09)62171-7

doi: 10.1097/chi.0b013e31805c7421

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 7 , Pages 831-839 , July 2007

Article Tools